Do you want to read an article? Please log in or register.
ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach
Lung, Respiratory and Thoracic Cancer
RECOMMENDED
Related content
Lung, Respiratory and Thoracic Cancer
Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study
Clin Cancer Res
Mack PC, Redman MW, Tukachinsky H, Kozono DE, Minichiello K, Dragnev KH, Tolba KA, Neal JW, Madison RW, Waqar SN, Aggarwal C, Hirsch FR, Patel JD, Herbst RS, Chiang AC, Reckamp KL, Kelly K, Borghaei H, Gray JE, Gandara DR
doi: 10.1158/1078-0432.CCR-24-3658
Lung, Respiratory and Thoracic Cancer
Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-blind, phase 3 trial
Lung Cancer
Liu T, He J, Wang Y, Yang Y, Zhang L, Shi M, Liu J, Sun D, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Huang Y, Fang W, Yang Y, Zhao Y, Zhang L
doi: 10.1016/j.lungcan.2025.108108
Lung, Respiratory and Thoracic Cancer
Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study
Lung Cancer
Uprety D, Abrahami D, Marcum ZA, Li B, Sang A, Davis M, Rifi N, Kelton JM, Ramaswamy K, Sanghvi P, Bazhenova L
doi: 10.1016/j.lungcan.2025.108436
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Avancini A, Giaj-Levra N, Minuti G, Pasqualini G, Colonese F, Federico AD, Fozza A, Montrone M, Olmetto E, Pastorello E, Reale ML, Riva ST, Roca E, Sini C, Viscardi G, Passiglia F, Pilotto S
doi: 10.1016/j.lungcan.2025.108531
Lung, Respiratory and Thoracic Cancer
Association of thyroid radiation dose with thyroid dysfunction in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy followed by maintenance immunotherapy
Lung Cancer
Yang G, Yoon HI, Lim SM, Hong MH, Cho J, Lee CG, Cho BC, Kim HR, Kim KH
doi: 10.1016/j.lungcan.2025.108574
Lung, Respiratory and Thoracic Cancer
Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study
Lung Cancer
Tambo Y, Sone T, Nishi K, Shibata K, Kita T, Araya T, Shirasaki H, Shimizu T, Yoneda T, Matsuoka H, Nanjo S, Koba H, Terada N, Ueda T, Nomura S, Murase Y, Yano S
doi: 10.1016/j.lungcan.2025.108422
Gastrointestinal Cancer
A tumor-naive ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study in CIRCULATE-Japan
Clin Cancer Res
Nakamura Y, Kaneva K, Lo C, Neems D, Freaney JE, Boulos H, Hyun SW, Islam F, Yamada-Hanff J, Driessen TM, Sonnenschein A, DeSantis DF, Kotani D, Watanabe J, Kotaka M, Mishima S, Bando H, Yamazaki K, Taniguchi H, Takemasa I, Kato T, Sangli C, Tell R, Blidner R, Yoshino T, Sasser K, Oki E, Nimeiri H
doi: 10.1158/1078-0432.CCR-24-2396
Lung, Respiratory and Thoracic Cancer
Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3
J Thorac Oncol
Gray JE, Markovets A, Reungwetwattana T, Majem M, Nogami N, Peled N, Lee JS, Cho BC, Chewaskulyong B, John T, Han JY, Sebastian M, Todd A, Rukazenkov Y, Barrett C, Chmielecki J, Lee SM, Ramalingam SS, Hartmaier R
doi: 10.1016/j.jtho.2024.07.008
Lung, Respiratory and Thoracic Cancer
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer
Clin Cancer Res
Pecci F, Thummalapalli R, Alden SL, Ricciuti B, Alessi JV, Elkrief A, Rizvi H, Wang X, Jeng M, Egger JV, Vaz VR, Barrichello A, Lamberti G, Di Federico A, Santo V, Rossato de Almeida G, Gandhi M, Clark P, Nishino M, Johnson BE, Hellmann M, Schoenfeld AJ, Awad MM
doi: 10.1158/1078-0432.CCR-24-2990